Recent Updates
Recently added Catalysts
BDX Positive Sentiment Score: 70/100

BD to Announce Financial Results for its Second Quarter of Fiscal 2023 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results...

Key Takeaway: Becton, Dickinson and Company (BD) has announced it will report its financial results for the second quarter of fiscal year 2023 on May 4, 2023. The results will be disseminated through a news release at 6:30 a.m. ET, followed by an audio webcast at 8 a.m. ET for further discussion. This announcement highlights BD's ongoing engagement with investors and stakeholders regarding its operational strategies and financial performance.

Market Sentiment Analysis

POSITIVE FACTORS

  • Announcement of upcoming financial results shows transparency.
  • Opportunity for stakeholders to engage through the audio webcast.
  • Company's commitment to improving health care delivery highlighted.

Full Press Release Details

FRANKLIN LAKES, N.J. , April 6, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it will report financial results for its second quarter of fiscal year 2023 on Thursday, May 4, 2023 . A news release will be issued at approximately 6:30 a.m. Eastern Time (ET) and will be available at www.bd.com/investors , along with related presentation materials. The news release and presentation materials will include summary financial information for the company's second quarter of fiscal year 2023, which ended on Friday, March 31, 2023.
BD management will host an audio webcast at 8 a.m. ET on May 4, 2023 to discuss its financial results and provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors and a replay will be available shortly after the call at the same website.
About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD , please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo .
Contacts:
Media : Investors :
Troy Kirkpatrick Francesca DeMartino
VP, Public Relations SVP, Head of Investor Relations
858.617.2361 201.847.5743
[email protected] [email protected]
SOURCE BD (Becton, Dickinson and Company)

21 %

Frequently Asked Questions

When will BD report its Q2 fiscal year 2023 results?

BD will report its financial results on May 4, 2023.

How can I access BD's financial results webcast?

The webcast will be available on BD's investor relations website.

What time will the financial results webcast start?

The audio webcast will begin at 8 a.m. ET on May 4, 2023.

What information will be in the news release?

The release will include financial summaries for Q2 of fiscal 2023.

What does BD focus on as a company?

BD innovates in medical technology to improve health care delivery and outcomes.

Last updated: Apr 6, 2023